Hologic's Narrow Economic Moat Remains Strong Thanks to Pandemic

Senior Equity Analyst

Debbie Wang

Under CEO Stephen MacMillan's watch, Hologic has been able to focus on structural competitive advantages, improve its balance sheet, and judiciously step into complementary markets, which has smoothed out the vagaries of product cycles. 

Though the purchase of Gen-Probe was pricey, Hologic now holds a strong position in a host of molecular diagnostic tests across women’s health, infectious disease, and oncology that run solely on its proprietary instrumentation. The technology platform came in handy during the pandemic, and Hologic has skillfully leveraged the opportunity to significantly increase Panther installations, which should pay off over the longer term. Further, Hologic controls roughly 65% of the U.S. digital mammography market and leads the way in 3D mammography. While 3D adoption has slowed, Hologic's clinical data still gives it an edge over its larger competitors, and there are still opportunities to sell ancillary accessories for mammograms and biopsies. 

However, Hologic faces secular and competitive hurdles. Recommended cervical screening intervals have lengthened, reducing Pap smear volume and forcing Hologic to preserve market share against Becton Dickinson. In addition, heavyweights General Electric and Siemens compete in the 3D mammography market, which could be challenging, given GE's entrenchment in select hospitals and ability to bundle an extensive menu of capital equipment.

While material, we think Hologic has done a good job of navigating the competitive pressures. Importantly, the pandemic opened an opportunity for the company to aggressively pursue enlarging its footprint in the molecular diagnostic market. Overwhelming demand for COVID-19 PCR tests allowed Hologic to expand its installed base by roughly 50%. The related boost in cash flow from these tests also opened the door for Hologic to make strategic purchases of a wider array of molecular diagnostic tests, which could pave the way for a more robust stream of recurring revenue after the pandemic that goes beyond Hologic's historical stronghold in testing for sexually transmitted diseases.

Business Strategy & Outlook

We believe Hologic has dug a narrow economic moat based on the switching costs and intellectual property that surround its breast health and diagnostics platforms. Hologic pioneered the first Food and Drug Administration-approved 3D mammography platform in the U.S. Mammography equipment such as this is typically a big-ticket purchase for hospitals and radiology clinics at price tags of $300,000 per digital unit and up to $450,000 per 3D installation, and the time to retrain on systems and reorganize workflow means that customers have little incentive to switch platforms. Furthermore, it will be considerably less expensive for Hologic’s 2D customers to upgrade their equipment rather than switch to a competing system. With a sizable installed base, the firm also reaps the benefits of five-year service contracts that annually cost about 10%-12% of the purchase price. While optional, more than 90% of its installed base falls under contract.

Additionally, lengthy FDA approval processes and the sophistication of the technology are tall barriers that deter new market entrants, though both General Electric and Siemens have received FDA approval for 3D systems. While this adds a new level of competition and could apply some pricing pressure, we think the growing body of clinical data for Hologic's Genius system helps to establish its superiority in the minds of clinicians. 

After acquiring Gen-Probe in 2012 and Cytyc before that, Hologic’s diagnostics division also leverages the high switching costs that surround its proprietary instrumentation and the tests that run on it. Adding to ThinPrep’s leading share in the liquid-based Pap market, Gen-Probe dramatically expanded Hologic’s diagnostic capabilities in HPV, chlamydia, gonorrhea, trichomonas, and blood screening. Once labs commit to the firm’s automated equipment to streamline operations, they run the company’s tests to consolidate workflow to fewer platforms. In addition to the time required to train lab technicians and adjust work flow, steep switching costs are built around instrumentation, with the $150,000 price tag built into per-reagent costs. This molecular diagnostics platform saw a boom during the COVID-19 crisis, and Hologic benefited from demand that significantly enlarged the firm's installed base of machines.

Hologic's 2017 acquisition of Cynosure provided a sizable footprint in the aesthetics market. However, we did not think this medical aesthetics business was worthy of a moat on its own, nor did we think the business bolstered Hologic's moat, because the cosmetic laser market is vulnerable to disruptive technology and has low barriers to entry, relatively low switching costs, and little clinical data to differentiate competitive products. Manufacturers compete primarily on the basis of marketing, which isn't necessarily Hologic's forte, in our view. We've mainly been relieved that Hologic decided to jettison the business three years ago, in favor of focusing on its existing footprints in molecular diagnostics and breast health.

We think Hologic’s remaining segments, surgical and skeletal health, do not have moats. The firm’s hysteroscopic surgical product, MyoSure, has led to pockets of success with strong cash flows. However, lower-cost alternatives have put pressure on its NovaSure product and adverse macroeconomic conditions have resulted in mixed skeletal results. Nevertheless, we believe Hologic’s breast health and diagnostics segments largely outweigh these drawbacks.

From an environmental, social, and governance perspective, we think there's little risk of these factors causing permanent impairment of Hologic's competitive advantages. However, some of the more vulnerable areas of risk would include the high quality standards that diagnostics makers must follow to ensure results are accurate and valid. As we saw with the Theranos debacle, inaccurate test results can lead to inappropriate medical treatment. This risk is mitigated for Hologic, however as its tests and equipment are regulated by the FDA. 

We believe Hologic's exposure to product governance risks has actually diminished now that it has divested its medical aesthetics business. The legacy Cynosure business fell into a gray area; though cosmetic lasers are regulated by the FDA, the use of such lasers is left up to the practitioners. In practice, this means practitioners would often use use those lasers off-label, for conditions or procedures for which they were never approved. This exposure for laser manufacturers is exacerbated by the patchwork of regulation regarding who is qualified to use these lasers, which varies by state. At present, just New Jersey requires that only trained medical doctors can use the lasers. In other states, nonphysicians can also operate these lasers, which becomes risky as the medical spas where many of these treatments take place are only loosely regulated on a state-by-state basis.

By divesting its aesthetic laser business, Hologic has taken a big step away from product governance risk, in our view.

Narrow

Economic Moat

Hologic

Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products dedicated to serve the healthcare needs of women. It operates through the following segments: Breast Health, Diagnostics, GYN Surgical, and Skeletal Health. The Breast Health segment includes a portfolio of solutions for breast cancer care for radiology, pathology, and surgery. The Diagnostics segment consists of products used to aid in the screening and diagnosis of human diseases. The GYN Surgical segment involves the NovaSure Endometrial Ablation System, the MyoSure Hysteroscopic Tissue Removal System, and the Fluent Fluid Management System. The Skeletal Health segment covers the Horizon DXA and the Fluoroscan Insight FD mini C-arm. The company was founded by S. David Ellenbogen and Jay A. Stein in 1985 and is headquartered in Marlborough, MA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Hologic exceeds Q1 earnings, eyes growth in women's health

Hologic's Q1 performance surpassed expectations, driven by strong organic growth and strategic initiatives. The company's commitment to women's health, financial strength, and focus on innovation position it well for future growth. Challenges in Breast Health highlight areas for improvement, while opportunities in new markets and products offer avenues for expansion.

Hologic surpasses Q2 expectations, eyes international growth and women's health

Hologic's Q2 performance exceeded expectations, driven by robust organic revenue growth and strong margins across divisions.
While facing challenges like COVID-related revenue declines and seasonal factors, the company's strategic strengths in women's health and international expansion present growth opportunities.
To sustain growth, Hologic must navigate macro uncertainties, balance growth drivers, and capitalize on opportunities in diagnostics and global expansion.
Overall, Hologic's solid financial results, increased revenue guidance, and strategic initiatives position the company for continued success in the healthcare market.

Hologic excels in Q3 earnings, eyes global growth amid challenges

Hologic delivered strong financial results in Q3 2023, driven by robust revenue growth and strategic product offerings across its divisions.
While facing margin challenges and geopolitical uncertainties, the company remains optimistic about sustaining growth and enhancing profitability through operational improvements.
With a focus on innovation, global expansion, and cautious M&A strategies, Hologic is well-positioned to capitalize on opportunities and navigate challenges in the healthcare market.

Hologic surpasses revenue targets, eyes international growth and strategic M&A

Hologic delivered strong financial performance in Q4 2023, exceeding revenue and EPS targets while emphasizing women's health and innovation.
The company's focus on international growth, strategic capital allocation, and product portfolio strength position it well for continued success.
Challenges in regulatory compliance, M&A decisions, and market dynamics require careful navigation for sustained growth.
Opportunities in international expansion, strategic M&A, and product innovation offer avenues for future growth and market leadership.

Hologic surpasses Q1 revenue expectations, eyes international growth opportunities

Hologic delivered strong Q1 2024 results, exceeding revenue guidance and showcasing robust financial performance with organic growth of 5.2% ex-COVID.
The company's focus on innovation, market expansion, and strong customer relationships positions it well for continued growth and success beyond COVID testing.
While facing challenges such as tough comps in Q2 and potential tax rate impacts, Hologic's disciplined growth strategies and commitment to transformative initiatives offer opportunities for future expansion.
With a strong emphasis on AI capabilities, market expansion, and strategic M&A, Hologic is poised for sustained growth and market leadership in the healthcare sector.

Hologic beats Q2 revenue targets, eyes international growth opportunities

Hologic exceeded revenue and EPS expectations in Q2 2024, showcasing growth in key business segments.
While facing challenges in certain revenue streams, the company is focused on international expansion and margin improvement.
Opportunities lie in leveraging international growth, strategic acquisitions, and product utilization trends.
Overall, Hologic's performance reflects resilience post-COVID and strategic focus on innovation and market positioning.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products dedicated to serve the healthcare needs of women. It operates through the following segments: Breast Health, Diagnostics, GYN Surgical, and Skeletal Health. The Breast Health segment is involved in a portfolio of solutions for breast cancer care for radiology, pathology, and surgery. The Diagnostics segment focuses on products used to aid in the screening and diagnosis of human diseases. The GYN Surgical segment offers the NovaSure Endometrial Ablation System, the MyoSure Hysteroscopic Tissue Removal System, and the Fluent Fluid Management System. The Skeletal Health segment covers the Horizon DXA and the Fluoroscan Insight FD mini C-arm. The company was founded by S. David Ellenbogen and Jay A. Stein in 1985 and is headquartered in Marlborough, MA.

On Wednesday, July 29, Hologic (NASDAQ: HOLX) will report its last quarter's earnings.

Hologic's Earnings Outlook

Strength in segmental business is likely to have aided Hologic's (HOLX) performance in third-quarter fiscal 2020 amid the coronavirus-led economic doldrums.

Can Diagnostics Aid Hologic (HOLX) Q3 Earnings Amid Coronavirus?

Hologic's (HOLX) latest cart-based ultrasound system enhances efficiency and accuracy to better meet the requirements of breast imagers and optimize patient care.

Hologic Expands Product Portfolio With New Ultrasound System

Despite a 90% rise since the March 23 lows of this year, at the current price of around $57 per share we believe the stock price of Hologic, best known for its medical devices for diagnostics, surgery, and medical imaging, has more room for growth. Hologic stock has rallied from $29 to $57 off the.

Buy, Sell Or Hold Hologic at $57?

Hologic stock rallied to a record high on Tuesday, signaling more gains are likely. Here's how to capitalize on more upside.

Buy Hologic Stock as it Blasts to a Record High

Cerner

Laboratory

Patterson Companies

Here are some MedTech stocks which might be a solid investment option post the coronavirus blues.

4 Cheap MedTech Stocks Poised to Beat Industry Post-Pandemic

Hologic (NASDAQ: HOLX) shares were trading higher Tuesday after Cowen  upgraded the stock from Market Perform to Outperform and announced a price target of $64 per share.

Why Hologic's Stock Is Trading Higher Today

Hologic has carved out a meaningful niche in women's health. But it's coronavirus testing driving HOLX stock higher these days.

Hologic Stock Rides High on Strength of Coronavirus Testing

IDEXX Laboratories

HOLX vs. IDXX: Which Stock Is the Better Value Option?

Keurig Dr Pepper Inc

Meritage Homes

Sally Beauty Hlds

Vistra Energy

By following broker ratings, you can find stocks that are likely to generate impressive returns.

5 Stocks With Upgraded Broker Ratings to Buy Right Away

Hologic stock has rallied around 83% over recent weeks (vs. about a 40% gain in the S&P 500) to its current level of $53 after falling to a low of $29 in late March as a rapid increase in the number of Covid-19 cases outside China resulted in heightened fears of an imminent global economic downturn.

What’s Next For Hologic After A 80% Rally?

Hologic, Inc. (HOLX) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

Moving Average Crossover Alert: Hologic

Abbott Labs

Which one of these COVID-19 test-kit manufacturers is a better investment?

Better Coronavirus Stock: Abbott Labs or Hologic?

ABIOMED

HOLX vs. ABMD: Which Stock Is the Better Value Option?

HOLX or ABMD: Which Is the Better Value Stock Right Now?

Hologic Inc. HOLX, +1.33% shares rose more than 2% in the extended session Monday after the maker of medical devices said its fiscal third-quarter's financial outlook has improved, mainly because one of its units is seeing more revenue related to COVID-19 tests.

Hologic's financial outlook improves thanks to coronavirus tests

Hologic (HOLX) reported earnings 30 days ago. What's next for the stock?

Why Is Hologic (HOLX) Up 4.4% Since Last Earnings Report?

The company's COVID-19 testing platform is just part of the reason for the stock's jump.

Hologic Is Trading Near Its All-Time High. Is It Still a Good Buy?

HOLX vs. ABMD: Which Stock Should Value Investors Buy Now?

Celyad

DexCom

NuCana

Teladoc

The health care industry has been rallying so far this year on constant testing and COVID-19 vaccine trials.

5 Health Care Stocks to Bet on as Coronavirus Woes Linger

Hologic (HOLX) expects to boost testing capacity by combining its manufacturing ability for the latest EUA of test with its largest installed base of high-throughput molecular instruments.

Hologic's Second Molecular Test Gets EUA to Detect Coronavirus

Shares of Hologic Inc. HOLX, +0.11% gained 1.9% in premarket trading on Friday after the company announced that it received its second emergency use authorization (EUA) for a COVID-19 test from the Food and Drug Administration.

Hologic shares rise on second COVID-19 test authorization

Hologic (HOLX) exhibits robust segmental growth in second-quarter fiscal 2020, fueled by strong performance by the Diagnostics segment amid the coronavirus pandemic.

Hologic (HOLX) Beats Q2 Earnings Estimates, Withdraws View

Hologic, Inc. (HOLX) CEO Stephen MacMillan on Q2 2020 Results - Earnings Call Transcript

Shares of Hologic Inc. HOLX, +0.54% rose more than 6% in the extended session Wednesday after the medical technology company met Wall Street expectations for its adjusted fiscal second-quarter profit and posted sales above forecasts, saying it will emerge from the pandemic as a "stronger company.

Hologic stock rallies as company beat sales views

Hologic (HOLX) delivered earnings and revenue surprises of 5.56% and 0.00%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

News for Hologic Stock (HOLX)